DEF 14A: Arrowhead Pharmaceuticals Reports Strong Financials, Advances Pipeline

Arrowhead Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders, highlighting significant financial improvements, key regulatory approvals, and pipeline advancements.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on Thursday, March 19, 2026, at 10:00 a.m., Pacific Time, with January 22, 2026, as the record date for voting.
• Key proposals include the election of seven directors, an advisory vote on executive compensation, approval of the Amended and Restated 2021 Incentive Plan, and ratification of KPMG LLP as independent auditors for fiscal year ending September 30, 2026.
• Douglas Ingram will retire from the Board, reducing its size to seven directors.
• The company completed upsized offerings of convertible senior notes, common stock, and pre-funded warrants, raising $930 million to strengthen its balance sheet and fund operations through multiple potential commercial launches.
• Interim results from Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7 showed promising data for obesity treatment, including doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat with ARO-INHBE in combination with tirzepatide.
• Plozasiran received Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia (SHTG) and FDA approval for REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS) on November 18, 2025, with subsequent approvals from Chinese NMPA and Health Canada.
• The company filed for regulatory clearance for ARO-DIMER-PA, the first clinical candidate to target two genes simultaneously in one molecule (PCSK9 and APOC3).
• Significant partnership milestones include a $200 million milestone from Sarepta for ARO-DM1 development, a $200 million upfront payment from Novartis for ARO-SNCA, a $100 million milestone from Sarepta for ARO-DM1 enrollment, and $130 million in revenue plus a $10 million milestone from Sanofi for plozasiran rights in Greater China.
• The Sarepta collaboration also included a $500 million upfront payment, a $325 million equity investment, and $250 million in annual installments over five years, with potential future milestones up to $10 billion.
• Fiscal 2025 revenue increased to $829.4 million from $3.6 million in fiscal 2024, and net loss significantly reduced to $1.6 million from $599.5 million in fiscal 2024.
• Cash, cash equivalents, restricted cash, and available-for-sale securities totaled $919.4 million at September 30, 2025.
• The CEO's fiscal 2025 annual total compensation was $9,029,861, resulting in a CEO to median employee pay ratio of 55:1.

Sentiment

Score: 8

Explanation: The company demonstrates exceptional operational and strategic execution, evidenced by a massive increase in revenue, a near break-even net loss, and a robust cash position. Key regulatory approvals and numerous high-value partnerships validate its platform and pipeline, substantially de-risking development programs. While a net loss was still reported and some commercial goals were missed, the overall strategic and financial achievements are highly positive.

Positives

• Upsized offerings of convertible senior notes, common stock, and pre-funded warrants raised $930 million, significantly strengthening the balance sheet and expected to provide funding through multiple potential commercial launches.
• Interim results from Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7 showed promising data for obesity treatment, including doubled weight loss and tripled reductions in visceral fat, total fat, and liver fat with ARO-INHBE in combination with tirzepatide.
• ARO-ALK7 achieved dose-dependent reductions in adipose ALK7 mRNA with a mean reduction of -88% at the 200 mg dose at week 8.
• Plozasiran received Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia (SHTG).
• FDA approved REDEMPLO (plozasiran) injection for Familial Chylomicronemia Syndrome (FCS) on November 18, 2025, supported by positive Phase 3 PALISADE study data (median change from baseline of -80% triglycerides vs. -17% in pooled placebo group).
• REDEMPLO also received approvals for the treatment of FCS from the Chinese National Medical Products Administration and Health Canada.
• Filed for regulatory clearance for ARO-DIMER-PA, the first clinical candidate to target two genes simultaneously in one molecule (PCSK9 and APOC3).
• Dosed first subjects in Phase 1/2a clinical trial of ARO-MAPT for tauopathies including Alzheimer's disease, utilizing a new proprietary delivery system for CNS penetration.
• Global licensing and collaboration agreement with Novartis for ARO-SNCA, including a $200 million upfront payment and eligibility for up to $2.0 billion in potential milestone payments plus royalties.
• Earned a $200 million milestone payment from Sarepta for ARO-DM1 development and a $100 million milestone payment for ARO-DM1 enrollment target.
• Asset purchase agreement with Sanofi for plozasiran rights in Greater China, generating $130 million in revenue and a $10 million milestone for REDEMPLO approval in China.
• Initiated Phase 3 clinical trial (YOSEMITE) for zodasiran in homozygous familial hypercholesterolemia (HoFH) and completed enrollment of SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical trials for plozasiran in sHTG.
• Interim results from ARO-C3 and ARO-CFB Phase 1/2 clinical studies showed dose-dependent reductions in target proteins and inhibition of alternative pathway activity.
• Sarepta collaboration included a $500 million upfront payment, a $325 million equity investment, and $250 million in annual installments over five years, plus potential future milestones up to $10 billion and tiered royalties.
• GSK triggered a $2.5 million milestone payment for a Phase 2 trial.
• Fiscal 2025 revenue increased significantly to $829.4 million from $3.6 million in fiscal 2024 and $240.7 million in fiscal 2023.
• Net loss dramatically reduced to $1.6 million in fiscal 2025 from $599.5 million in fiscal 2024 and $205.3 million in fiscal 2023.
• Net loss per share improved to ($0.01) in fiscal 2025 from ($5.00) in fiscal 2024 and ($1.92) in fiscal 2023.
• Strong cash position with $919.4 million at September 30, 2025.

Negatives

• Commercial goals for REDEMPLO's approval and product revenue were not met because they assumed priority review instead of standard review.
• The company reported a net loss of $1.6 million in fiscal 2025, despite significant revenue growth.
• If the Amended and Restated 2021 Incentive Plan is approved, the company's overhang (potential dilution from equity awards) would increase to 11.8% from 5.6%.

Risks

• The company's ability to attract and retain highly skilled individuals in competitive labor markets is dependent on equity awards, and failure to approve the Amended and Restated 2021 Incentive Plan could disrupt compensation programs and limit retention incentives.
• Forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially, including those identified in the company's Annual Report on Form 10-K.
• Potential for 'parachute payments' under Section 280G of the Internal Revenue Code in connection with a change of control, which may be subject to an additional 20% federal tax and may be non-deductible to the Company.
• The loss of existing or potential profit in Awards will not constitute an element of damages in the event of termination of Employment for any reason, even if the termination is in violation of an obligation of the Company or any Affiliate to the Participant.
• The Administrator (Compensation Committee) may cancel, rescind, withhold, or otherwise limit or restrict any Award at any time if the Participant is not in compliance with applicable provisions or breaches any agreement with the Company or its Affiliates.

Future Outlook

The $930 million capital raise is expected to provide funding through multiple potential commercial launches. The proposed Amended and Restated 2021 Incentive Plan, if approved, is anticipated to provide sufficient shares for future equity grants for approximately the next five years. The company will continue to assess its environmental impact and operate sustainably, and the Board will consider stockholder feedback on executive compensation for future arrangements.

Management Comments

• "We believe that the compensation of our executive officers should be directly linked to the achievement of specific objectives that are expected to increase stockholder value."
• "We strongly believe that the approval of this proposal [Amended and Restated 2021 Incentive Plan] is instrumental to our continued success."
• "By hosting the Annual Meeting virtually, we believe we can expand access, improve communication and lower costs, while reducing the environmental impact of the meeting."
• "Our philosophy has been to foster this expectation with reasonably aggressive incentive compensation."
• "We believe that, ultimately, the creation of sustainable long-term stockholder value will depend on our ability to successfully bring to market the products we develop or our success in partnering with strategic collaborators to bring them to market."
• "The Compensation Committee believes the structure aligns compensation according to the level of service contributions by each director."

Industry Context

Arrowhead Pharmaceuticals operates in the highly competitive biotechnology and pharmaceutical sector, specializing in RNAi-based therapeutics for intractable diseases. Its proprietary TRiM platform aims to provide competitive advantages in drug discovery, delivery, and manufacturing across various tissue types, including liver, lung, muscle, and CNS. The company's strategy involves both wholly-owned pipeline development and strategic collaborations with major pharmaceutical partners like Sarepta, Novartis, Sanofi, Takeda, Amgen, and GSK, a common approach in biotech to de-risk and fund extensive R&D. The recent FDA approval of REDEMPLO for FCS positions it in the rare disease market, while other programs target larger indications such as obesity and Alzheimer's disease, reflecting a diversified therapeutic focus. The company's executive compensation practices are benchmarked against a peer group of publicly-held U.S. biotechnology/pharmaceutical companies with comparable market capitalizations and clinical/commercial stages.

Comparison to Industry Standards

• The average total compensation paid to the company's non-executive directors for service in 2025 is at or below the 60th percentile of the total compensation paid to non-executive directors of its peer group.
• The company's five-year total stockholder return (TSR) as of September 30, 2025, was at the 48th percentile of its peer group.
• The company's three-year average burn rate for fiscal years 2023, 2024, and 2025, was approximately 1.63%, a metric often compared to industry averages for equity compensation utilization.
• The company's overhang as of January 15, 2026, was 5.6%, which would increase to 11.8% if the Amended and Restated 2021 Incentive Plan is approved, figures typically benchmarked against industry norms for potential dilution.
• The company generally evaluates the compensation of its executive officers relative to the median of the competitive market, though it does not target compensation at any specific level relative to the competitive market.

Management Changes

Corporate Governance

Related Party Transactions

• Dr. Bruce Given, brother of former Director and Chairman Dr. Douglass Given, transitioned to a consultant role on August 1, 2025, for a yearly fee of $280,000. He earned $887,227 in base salary, bonus, and consulting fees during fiscal year 2025 and was awarded 100,000 RSUs.
• Vincent Anzalone, brother of CEO Christopher Anzalone, serves as Senior Vice President, Investor Relations and Corporate Communications. He earned $417,568 in base salary and bonus during fiscal year 2025 and was awarded 25,000 RSUs in fiscal 2025 and 21,000 RSUs in January 2026.
• Christopher Anzalone, CEO, pledged 1,192,897 shares of Common Stock as collateral for a line of credit.

Stakeholder Impact

• Shareholders: Direct impact from voting on director elections, executive compensation, and the Amended and Restated 2021 Incentive Plan. Significant positive impact from strong financial performance, successful capital raises, and numerous milestone payments. Potential dilution from the proposed increase in shares for the incentive plan (overhang increases from 5.6% to 11.8%).
• Employees: Benefit from the proposed Amended and Restated 2021 Incentive Plan, which is vital for attracting and retaining talent with equity incentives. The company offers competitive compensation, benefits, internal advancement, individualized development opportunities, and internships.
• Customers/Patients: Potential benefit from the advancement of multiple drug candidates, including REDEMPLO's FDA approval for FCS, plozasiran's Breakthrough Therapy designation for SHTG, and pipeline progress for diseases like Alzheimer's and obesity.
• Creditors: Strengthened balance sheet with a $930 million capital raise and a robust cash position of $919.4 million, enhancing financial stability.
• Regulatory Authorities: The company's adherence to SEC and Nasdaq rules for corporate governance, executive compensation, and financial reporting is demonstrated through this proxy statement.

Next Steps

• Stockholders will vote on the election of seven directors at the 2026 Annual Meeting on March 19, 2026.
• Stockholders will conduct an advisory (non-binding) vote to approve executive compensation at the 2026 Annual Meeting.
• Stockholders will vote on the approval of the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan at the 2026 Annual Meeting.
• Stockholders will ratify the selection of KPMG LLP as independent auditors for the fiscal year ending September 30, 2026, at the 2026 Annual Meeting.
• The company will continue to develop and advance its pipeline and partnered candidates, including ongoing Phase 1/2a trials for ARO-INHBE and ARO-ALK7 for obesity.
• The company will continue Phase 3 studies for plozasiran in sHTG (SHASTA-3, SHASTA-4, SHASTA-5, and MUIR-3) and the Phase 3 clinical trial (YOSEMITE) for zodasiran in HoFH.
• The company will continue to investigate ARO-C3 and ARO-CFB in Phase 1/2a clinical trials for complement mediated diseases and ARO-RAGE in a Phase 2a clinical trial.
• The company will continue to investigate ARO-PNPLA3 in clinical trials for MASH and ARO-MAPT in a Phase 1/2a clinical trial for tauopathies.
• The company will initiate a Phase 1/2a clinical trial of ARO-DIMER-PA for mixed hyperlipidemia.
• Sarepta will continue co-development and commercialization of ARO-DUX4, ARO-DM1, ARO-MMP7, and ARO-ATXN2, and develop ARO-HTT, ARO-ATXN1, and ARO-ATXN3.
• Takeda is conducting multiple Phase 3 studies for fazirsiran (ARO-AAT) for AATD liver disease (REDWOOD study).
• Amgen is evaluating olpasiran in a Phase 3 study (OCEAN) for major cardiovascular events.
• GSK is conducting Phase 2b clinical trials for GSK-4532990 (ARO-HSD) in MASH and alcohol-related liver disease, and initiated a Phase 2 study of daplusiran/tomligisiran followed by bepirovirsen in patients with chronic hepatitis B.
• The Compensation Committee and Board will consider the outcome of the Say-on-Pay vote when determining future executive compensation arrangements.
• The company will file a registration statement on Form S-8 if the Amended and Restated 2021 Incentive Plan is approved.
• The company will disclose future amendments to its Code of Conduct and waivers granted to officers and directors on its website.

Key Dates

Recommendation

The company demonstrates exceptional operational and strategic execution, evidenced by a massive increase in revenue, a near break-even net loss, and a robust cash position. Key regulatory approvals for REDEMPLO and Breakthrough Therapy designation for plozasiran validate its RNAi platform and pipeline. The numerous high-value partnerships with major pharmaceutical companies (Sarepta, Novartis, Sanofi, Takeda, Amgen, GSK) provide significant non-dilutive funding and external validation of its technology, substantially de-risking its development programs. The advancement of a broad and innovative pipeline, including dual-gene targeting and CNS penetration, indicates strong future growth potential. While the proposed incentive plan increases potential dilution, the overall strategic and financial achievements far outweigh this, positioning the company for continued success and strong shareholder value creation.

Keywords

Arrowhead Pharmaceuticals, Proxy Statement, Annual Meeting, Executive Compensation, Incentive Plan, RNAi Therapeutics, Drug Development, Clinical Trials, REDEMPLO, Plozasiran, Familial Chylomicronemia Syndrome, Severe Hypertriglyceridemia, Obesity, Tauopathies, Alzheimer's Disease, Parkinson's Disease, Sarepta Therapeutics, Novartis, Sanofi, TRiM platform, Biotechnology, Pharmaceuticals, Corporate Governance, Financial Results, Milestone Payments, Capital Raise